indazoles and s 1033
indazoles has been researched along with s 1033 in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Robert, C; Sibaud, V | 1 |
| Li, J | 1 |
| Alcoser, SY; Borgel, S; Bottaro, DP; Chen, AP; Chen, L; Chuaqui, R; Doroshow, JH; Ferry-Galow, KV; Hollingshead, MG; Kinders, RJ; Konaté, MM; Kummar, S; Lawrence, SM; Makhlouf, HR; Miller, SB; Navas, T; Parchment, RE; Rubinstein, L; Srivastava, AK; Subramanian, J; Vilimas, T; Voth, AR; Wilsker, DF | 1 |
| Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E | 1 |
Reviews
1 review(s) available for indazoles and s 1033
| Article | Year |
|---|---|
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Other Studies
3 other study(ies) available for indazoles and s 1033
| Article | Year |
|---|---|
[Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].
Topics: Benzimidazoles; Exons; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Indazoles; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolones; Succinate Dehydrogenase; Sulfonamides | 2016 |
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Biopsy, Large-Core Needle; Cadherins; Carcinoma; Cell Line, Tumor; Cell Plasticity; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Indazoles; Male; Mice; Neoplastic Stem Cells; Paclitaxel; Pyrimidines; Sulfonamides; Vimentin; Xenograft Model Antitumor Assays | 2020 |
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States | 2020 |